Decrease of 5-Hydroxymethylcytosine Is Associated with Progression of Hepatocellular Carcinoma through Downregulation of TET1

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Liu, Chungang ^a   Liu, Limei ^a   Chen, Xuejiao ^a   Shen, Junjie ^a   Shan, Juanjuan ^a   Xu, Yanmin ^a   Yang, Zhi ^a   Wu, Lin ^a   Xia, Feng ^a   Bie, Ping ^a   Cui, Youhong ^a   Bian, Xiu wu ^a   Qian, Cheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; ALPHA FETOPROTEIN; DIETHYLNITROSAMINE; MEMBRANE PROTEIN; PROTEIN TET1; PROTEIN TET2; PROTEIN TET3; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER TISSUE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ENZYME ANALYSIS; ENZYME SPECIFICITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; RAT; RECURRENT CANCER; THROMBOSIS; TUMOR INVASION;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOSINE; DIETHYLNITROSAMINE; DISEASE PROGRESSION; DNA METHYLATION; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RATS, WISTAR;

EID: 84877336241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062828     Document Type: Article

References (19)

1. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
2. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, et al. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930-935.
3. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, et al. (2010) Role of Tet proteins in 5 mC to 5 hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466: 1129-1133.
4. Globisch D, Münzel M, Müller M, Michalakis S, Wagner M, et al. (2010) Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLOS ONE 5: e15367.
5. Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, et al. (2011) Selective chemical labeling reveals the genome wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 29: 68-72.
6. Ito S, Shen L, Dai Q, Wu SC, Collins LB, et al. (2011) Tet proteins can convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine. Science 333: 1300-1303.
7. He YF, Li BZ, Li Z, Liu P, Wang Y, et al. (2011) Tet-mediated formation of 5-Carboxylcytosine and its excision by TDG in mammalian DNA. Science 333: 1303-1307.
8. Tan L, Shi YG, (2012) Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development. 139: 1895-1902.
9. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, et al. (2011) Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2: 627-637.
10. Yang H, Liu F, Bai F, Zhang JY, Ma SH, et al. (2013) Tumor development is associated with decrease of TET gene expression and 5-methlcytosine hydroxylation. Oncogene 32: 663-669.
11. Xu Y, Wu F, Tan L, Kong L, Xiong L, et al. (2011b) Genome-wide regulation of 5 hmC, 5 mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 42: 451-464.
12. Lian CG, Xu Y, Ceol C, Wu F, Larson A, et al. (2012) Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150: 1135-1146.
13. Xu W, Yang H, Liu Y, Yang Y, Wang P, et al. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17-30.
14. Sun L, Hyeon JL, Jae-Hoon K, Hyo-Suk L, Ja JJ, et al. (2003) Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 163: 1371-1378.
15. Shan J, Shen J, Liu L, Xia F, Xu C, et al. (2012) Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 56: 1004-1014.
16. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
17. Iyer LM, Thiliani M, Rao A, Aravind L, (2009) Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell cycle 8: 1698-1710.
18. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
19. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.